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Medication  
Class Medication
Member Home Physician Office Hospital Outpatient
Unique  
Utilizers ClaimsACPC MCPC ACPC MCPC ACPC§ MCPC§ Claims with  an Outlier§
IVIG
Gammagard S/D®‡ $7,792* $7,654* $7,815* $7,677*
Pending Pending 56%
139 701
Gammagard®‡ $4,962 $3,980 $4,985 $4,003
Gammaked®‡ $8,715* $8,715* $8,737* $8,737*
Pending Pending 7%
Gamunex-C®‡ $7,782 $7,444 $7,805 $7,466
Privigen® $6,004* $6,004* $6,027* $6,027* Pending Pending 100%*
Immuno-
modulators
Actemra® (tocilizumab) $1,320* $1,196* $3,077* $3,077* Pending Pending 17%
365 1,209
Entyvio® (vedolizumab) $6,435* $5,479* $6,489* $5,532* Pending Pending 100%
Orencia® (abatacept) $3,918* $4,006* $3,972* $4,060* Pending Pending 69%
Remicade® (infliximab) $5,844 $4,587 $5,919 $4,663 Pending Pending 89%
Others
Rituxan® (rituximab) $12,197* $8,746* $12,338* $8,887* Pending Pending 90%
166 406Soliris® (eculizumab) $35,816*  $25,718* $35,870* $25,771* Pending Pending 79%
Tysabri® (natalizumab) $5,665 $5,628 $5,688 $5,651 Pending Pending 79%
DISCUSSION
 ■ Massachusetts Medicaid reimburses for hospital outpatient services using APEC,  
an episode-specific, all-inclusive payment for each episode.2 
• APEC = Episode-Specific Total Enhanced Ambulatory Patient Grouping (EAPG) Payment + 
Outlier Component (if applicable).2
• The EAPG system uses ICD-10 codes and Healthcare Common Procedure Coding System 
(HCPCS) codes (including J-codes) to group similar services for reimbursement.3
• Medications are grouped into one of 22 EAPG drug categories (based on cost, clinical 
similarity, and substitutability), with each category assigned a weight to determine 
reimbursement.4
 ■ The initial results for the hospital outpatient SOC did not conform with anticipated 
findings and given the complexity of the APEC billing methodology, the final results  
for the hospital outpatient SOC are pending further review and evaluation.
 ■ The ACPCs and MCPCs were similar in the member home and physician office SOCs  
for all medications evaluated (Table 1; Figures 1 and 2).
 ■ The PMPM costs for all IVIG and immunomodulators evaluated were similar in the 
member home and physician office SOCs (Figures 3 and 4).
LIMITATIONS
 ■ With the current EAPG system, hospital outpatient facilities may be reimbursed more than 
the acquisition cost of some medications and less than the acquisition cost of others.
• Medications selected for this analysis may not be representative of all medications in terms  
of overall SOC cost trends.
 ■ The unique payment structure in the hospital outpatient SOC makes it challenging to 
compare costs across SOCs or extrapolate to other plans.   
 ■ This analysis evaluated a short study time frame during which there was no utilization  
for some medications in some SOCs.
 ■ There were limited physician claims for medications and, as a result, medication costs 
through pharmacy claims were used to calculate ACPCs and MCPCs for most medications 
in the physician office SOC.
OBJECTIVES
 ■ To evaluate the costs associated with the administration of select high-cost infused 
medications in three SOCs among the Massachusetts Medicaid FFS and PCC plans 
populations.
METHODS
 ■ This retrospective analysis included pharmacy and medical claims data for select high-cost 
infused medications between April 1, 2017 and September 30, 2017.
• Paid claims for abatacept, belimumab, eculizumab, golimumab for infusion, infliximab-abda, 
infliximab-dyyb, infliximab, intravenous immune globulins (IVIG), natalizumab, rituximab  
(non-oncology indications), tocilizumab, and vedolizumab were included.
• All paid claims with third-party liability coverage (regardless of SOC) and 340B claims in the 
member home and physician office SOCs were excluded.
• Claims for immune globulins administered subcutaneously in the member home or physician 
office SOCs were excluded. These claims could not be excluded in the hospital outpatient 
SOC.
 ■ The average cost per claim (ACPC) and median cost per claim (MCPC) were calculated for 
each medication in each SOC as follows:
• Member home SOC = medication cost (from pharmacy claims) + allowed home 
administration fee. 
• Physician office SOC = medication cost (from pharmacy claims or physician office claims) + 
allowed physician administration fee.
 – Two separate calculations were performed for this SOC with the higher of the ACPC and 
MCPC results included for analysis.
• Hospital outpatient SOC = adjudicated payment per episode of care (APEC) + allowed 
professional service fees.
 ■ The per member per month (PMPM) cost for each medication in each SOC was calculated 
using the following methodology:
• PMPM = total amount paid ÷ number of unique utilizers ÷ six months.
 ■ Statistical analysis:
• Descriptive statistics (including box and whisker plots) were used to report ACPCs and 
MCPCs while the Kruskal-Wallis and Dunn’s tests will be used to compare the MCPCs for  
each medication in each SOC.
RESULTS
CONCLUSIONS
 ■ This preliminary analysis suggests that for the Massachusetts Medicaid FFS and PCC 
plans, the costs associated with the administration of the selected high-cost medications 
evaluated were similar in the member home and physician office SOCs.  
 ■ Based on the initial findings, further study is required to fully evaluate the hospital 
outpatient EAPG payment system and to make overall conclusions about the least 
expensive SOC. 
FUTURE STUDIES
 ■ An expanded analysis will be performed to evaluate the costs associated with the 
administration of medications from all 22 EAPG drug categories in each SOC.  
This review will allow for overall conclusions regarding SOC cost trends. 
BACKGROUND
 ■ According to a nationwide 2017 survey, 58 respondent commercial health plans attribute 
almost half of specialty drug costs to the medical benefit (45%) with the remainder 
attributed to the pharmacy benefit (55%).1
 ■ Site of care (SOC) programs are one of many strategies used by payers to reduce specialty 
drug spend. These programs aim to shift utilization of high-cost infused medications to  
less costly sites of administration.1 
 ■ While the cost-savings associated with SOC programs are described in the literature for 
commercial insurers, data is lacking on their impact in Medicaid programs.
 ■ The Massachusetts Medicaid Fee-for-Service (FFS) and Primary Care Clinician (PCC) plans 
do not currently manage drug spend through an SOC program.
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Table 1: ACPC and MCPC for Select High-cost Infused Medications by SOC# 
82% of all claims were administered  
in the hospital outpatient SOC
Final results pending 
further evaluation
Figure 1: ACPC and MCPC for IVIG by SOC Figure 2: ACPC and MCPC for Immunomodulators by SOC
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Figure 3: PMPM Cost for IVIG by SOC
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Member Home Physician Office Hospital Outpatient
Gammagard S/D®‡ $5,195 $3,898 Pending
Gammagard®‡ $3,917 $3,898 Pending
Gammaked®‡ $2,905 $6,414 Pending
Gamunex-C®‡ $6,744 $6,414 Pending
Privigen® $7,005 $7,032 Pending
Figure 4: PMPM Cost for Immunomodulators by SOC
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Member Home Physician Office Hospital Outpatient
Actemra® (tocilizumab)    $770    $876 Pending
Entyvio® (vedolizumab) $2,360 $2,379 Pending
Orencia® (abatacept) $2,394 $1,836 Pending
Remicade® (infliximab) $2,901 $2,669 Pending
Mean
Median
Mean
Median
